Diagnosed with bone cancer at 14, college setter Gabby Orlet shares how volleyball, honesty and her family carried her through years of treatment.
|Articles|March 29, 2023
Myeloma News: From Iceland to China
Advertisement
In this blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie highlights the IMF-funded iStopMM (Iceland Screens Treats or Prevents Multiple Myeloma) study on the prevalence of smoldering multiple myeloma (SMM) based on a nationwide screening of over 75,000 Icelandic individuals aged 40 and above. He also discusses the CAR T product GC012F from China receiving FDA clearance for its IND application.
Advertisement
Related to this article
In the phase 3 RT CHARM trial, published Oct. 12, 2026, in the Journal of Clinical Oncology, a three-week course of radiation after mastectomy caused about the same rate of reconstruction complications as the standard five-week course in women with breast cancer.
Since September 2024, every U.S. mammogram report must tell patients whether their breast tissue is dense. Here is what that notice means, why it matters and what to ask your care team.
Noah Elliott, now a Paralympic snowboarder, counted small wins during inpatient chemotherapy and found inspiration in the youngest children on his hospital floor.
Diagnosed with stage 4 breast cancer weeks after giving birth, Eileen Carter and her chaplain husband share why a second opinion changed everything.
Five colorectal cancer trials recently began treating patients, testing targeted drugs, bispecific antibodies and immunotherapy. Here’s what each one is studying.
The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.
A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.
Advertisement
Advertisement
Trending on CURE
1
What Is a Personalized Cancer Vaccine? What Patients Should Know
2
Why Biomarker Testing Can Change a Brain Tumor Diagnosis
3
FDA Flags Possible Colitis Risk With CDK4/6 Breast Cancer Drugs
4
5 New Colorectal Cancer Clinical Trials to Know About
5